Current Perspectives, Challenges and Advances in Cell Based Therapies

Cell-based immunotherapy is based on the seemingly simple principle of harnessing the power of the immune system to combat cancer, and is emerging as an important clinical tool. The remarkable success of CAR-T cell therapies demonstrate that cell based therapies are effective at eradicating hematolo...

Full description

Saved in:
Bibliographic Details
HerausgeberIn:
Sonstige:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (192 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545832404498
ctrlnum (CKB)5400000000045193
(oapen)https://directory.doabooks.org/handle/20.500.12854/73716
(EXLCZ)995400000000045193
collection bib_alma
record_format marc
spelling Trikha, Prashant edt
Current Perspectives, Challenges and Advances in Cell Based Therapies
Frontiers Media SA 2020
1 electronic resource (192 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Cell-based immunotherapy is based on the seemingly simple principle of harnessing the power of the immune system to combat cancer, and is emerging as an important clinical tool. The remarkable success of CAR-T cell therapies demonstrate that cell based therapies are effective at eradicating hematological malignancies, and therefore hold great promise for other cancers. However, there are number of challenges that limit the full potential of cell based therapies, especially for solid cancers. T cells and NK cells represent major lymphocyte populations that are involved in immune surveillance and tumor eradication, and both are emerging as important players for cell based immunotherapy. Although they use different mechanisms for recognizing cancer cells, they complement each other during tumor eradication. NK cells have many functional similarities to T cells and represent the closest innate immune cell lineage to adaptive immune cell populations. Transcriptome analysis has also revealed similar phylogenetic origin of the two lymphocyte populations. The hurdles that impact therapeutic success of these cells include trafficking of lymphocytes to the tumor sites, recognition of solid tumors, and overcoming the inhospitable tumor microenvironment (TME) including the presence of suppressive cells (Treg and MDSC) and immune suppressive cytokines (TGFβ). The full potential of cell based therapies may be realized once tools to overcome these barriers are developed. This Research Topic collects articles critically examining these obstacles and the novel strategies being developed for cell-based therapies to overcome them.
English
Medicine bicssc
Oncology bicssc
immunotherapy
NK cell
tumor micoenvironment
CAR (chimeric antigen receptor) T cells
cell based therapy
2-88963-564-3
Thakar, Monica edt
Russell Cruz, Conrad edt
Trikha, Prashant oth
Thakar, Monica oth
Russell Cruz, Conrad oth
language English
format eBook
author2 Thakar, Monica
Russell Cruz, Conrad
Trikha, Prashant
Thakar, Monica
Russell Cruz, Conrad
author_facet Thakar, Monica
Russell Cruz, Conrad
Trikha, Prashant
Thakar, Monica
Russell Cruz, Conrad
author2_variant p t pt
m t mt
c c r cc ccr
author2_role HerausgeberIn
HerausgeberIn
Sonstige
Sonstige
Sonstige
title Current Perspectives, Challenges and Advances in Cell Based Therapies
spellingShingle Current Perspectives, Challenges and Advances in Cell Based Therapies
title_full Current Perspectives, Challenges and Advances in Cell Based Therapies
title_fullStr Current Perspectives, Challenges and Advances in Cell Based Therapies
title_full_unstemmed Current Perspectives, Challenges and Advances in Cell Based Therapies
title_auth Current Perspectives, Challenges and Advances in Cell Based Therapies
title_new Current Perspectives, Challenges and Advances in Cell Based Therapies
title_sort current perspectives, challenges and advances in cell based therapies
publisher Frontiers Media SA
publishDate 2020
physical 1 electronic resource (192 p.)
isbn 2-88963-564-3
illustrated Not Illustrated
work_keys_str_mv AT trikhaprashant currentperspectiveschallengesandadvancesincellbasedtherapies
AT thakarmonica currentperspectiveschallengesandadvancesincellbasedtherapies
AT russellcruzconrad currentperspectiveschallengesandadvancesincellbasedtherapies
status_str n
ids_txt_mv (CKB)5400000000045193
(oapen)https://directory.doabooks.org/handle/20.500.12854/73716
(EXLCZ)995400000000045193
carrierType_str_mv cr
is_hierarchy_title Current Perspectives, Challenges and Advances in Cell Based Therapies
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
noLinkedField
noLinkedField
_version_ 1796651970652536832
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02852nam-a2200397z--4500</leader><controlfield tag="001">993545832404498</controlfield><controlfield tag="005">20231214133045.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202111s2020 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000045193</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/73716</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000045193</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Trikha, Prashant</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Current Perspectives, Challenges and Advances in Cell Based Therapies</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (192 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cell-based immunotherapy is based on the seemingly simple principle of harnessing the power of the immune system to combat cancer, and is emerging as an important clinical tool. The remarkable success of CAR-T cell therapies demonstrate that cell based therapies are effective at eradicating hematological malignancies, and therefore hold great promise for other cancers. However, there are number of challenges that limit the full potential of cell based therapies, especially for solid cancers. T cells and NK cells represent major lymphocyte populations that are involved in immune surveillance and tumor eradication, and both are emerging as important players for cell based immunotherapy. Although they use different mechanisms for recognizing cancer cells, they complement each other during tumor eradication. NK cells have many functional similarities to T cells and represent the closest innate immune cell lineage to adaptive immune cell populations. Transcriptome analysis has also revealed similar phylogenetic origin of the two lymphocyte populations. The hurdles that impact therapeutic success of these cells include trafficking of lymphocytes to the tumor sites, recognition of solid tumors, and overcoming the inhospitable tumor microenvironment (TME) including the presence of suppressive cells (Treg and MDSC) and immune suppressive cytokines (TGFβ). The full potential of cell based therapies may be realized once tools to overcome these barriers are developed. This Research Topic collects articles critically examining these obstacles and the novel strategies being developed for cell-based therapies to overcome them.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Oncology</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NK cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor micoenvironment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR (chimeric antigen receptor) T cells</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cell based therapy</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88963-564-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thakar, Monica</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Russell Cruz, Conrad</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Trikha, Prashant</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thakar, Monica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Russell Cruz, Conrad</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:41:07 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338102240004498&amp;Force_direct=true</subfield><subfield code="Z">5338102240004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338102240004498</subfield></datafield></record></collection>